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OBJECTIVES To test one-month outcomes in a single center for their statistical power to corroborate
conclusions derived from large multicenter databases.
BACKGROUND Only with large, multicenter databases has it been possible to demonstrate more frequent
occurrences of complications in patients treated by “low-volume operators.” Critics feel that
such analyses mask excellent performance by many “low-volume operators.”
METHODS In a high-volume cardiac catheterization laboratory in a large, nonuniversity teaching
hospital, baseline clinical and angiographic characteristics were collected for a consecutive
series of 1,029 patients treated by 37 percutaneous transluminal coronary intervention (PTCI)
operators over a four-month period. One-month follow-up was obtained in 967 (94%)
patients who form the basis for this analysis.
RESULTS Only the group of operators performing ,50 cases annually had a major adverse cardiac event
(MACE) (death, myocardial infarction or symptom-driven revascularization) rate at one
month significantly greater than predicted from baseline characteristics. (Observed rate:
15.1%, expected: 9.7%, 95% confidence interval [CI]: 4.7%, 14.6%.) The difference was
driven by the significantly more frequent rate at which repeat revascularization was performed
in patients treated by that group of operators (observed: 13.8%, expected: 7.1%, 95% CI:
2.8%, 11.4%).
CONCLUSIONS As is true of analyses of large multicenter databases, lower volume operators as a group have
less good outcomes than those performing more. The greater statistical power provided by
one-month MACE rate offers advantages over the use of in-hospital complications for the
analysis of operator performance. (J Am Coll Cardiol 1999;34:1916–23) © 1999 by the
American College of Cardiology
Despite strong evidence for an inverse relationship between
operator volume and outcomes of percutaneous transluminal
coronary intervention (PTCI), controversy remains. The
debate has focused on the recent report of an expert panel of
the American College of Cardiology (1). That group rec-
ommended that, to maintain competence in this procedure,
an operator should perform a minimum of 75 PTCI
procedures annually. Four published analyses of large mul-
ticenter databases (2–5) form the basis for their recommen-
dation. Each analysis assessed the relationship of operator
volume to in-hospital complications in several thousands of
patients.
Many cardiologists have questioned the fairness of apply-
ing this standard to individual physician credentialling on
several grounds. First, they point out that the excellent
performance of many operators performing fewer than 75
cases annually may be obscured in such large conglomerates
of data. Individual “low-volume operators” may have excel-
lent results particularly in “high-volume” laboratories (2,6).
Second, in a related argument, critics suggest that multi-
center analyses may obscure a variety of laboratory-
dependent factors that may influence outcome. Finally,
critics contend that proper risk adjustment (a fundamental
necessity in outcomes analysis) may not be effectively
accomplished using multicenter data since consistent and
complete collection of baseline clinical and angiographic
characteristics of patients may be problematic.
Statistical obstacles also stand in the way of fair assess-
ment of the performance of “low-volume operators” when
the rate of in-hospital complications is the outcome variable
of interest. Since these events occur with a frequency of less
than 5% (7), only the large number of patients that typically
are available from multicenter studies provides the statistical
power to detect differences in performance between groups
of operators (8,9). The necessity for risk adjustment adds to
From the Section of Cardiology, the Washington Hospital Center, Washington,
DC. This study was supported by a grant from the Medlantic Research Institute,
Washington, DC. The data in this study were presented, in part, at the 71st Annual
Scientific Sessions of the American Heart Association, Dallas, Texas, November,
1998.
Manuscript received February 9, 1999; revised manuscript received June 14, 1999,
accepted August 25, 1999.
Journal of the American College of Cardiology Vol. 34, No. 7, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00449-0
the statistical dilemma since multivariate analysis requires
large data sets (10).
We sought to overcome the statistical problems inherent
in the use of infrequent in-hospital complications as the
outcome variable by replacing it with one-month adverse
events. Furthermore, we felt that an experience collected in
a single center would both eliminate the possibility of
variability in operator performance related to differences in
institutional practice inherent in multicenter databases and
allow a more consistent collection of baseline characteristics
for risk adjustment.
We believe one-month event rates to be a valid index of
operator performance for two reasons: first, since both
angiographic (11,12) and intravascular ultrasound data (13)
support a conclusion that neither restenosis nor progression
of disease is common within one month of PTCI, it is
reasonable to conclude that adverse events occurring within
that month are related either to the procedure or to patient
selection. Second, from the standpoint of patient satisfac-
tion, one-month results may be a more ideal criterion for
successful PTCI than merely freedom from in-hospital
complications. Unlike previous analyses, we included
symptom-driven repeat PTCI within the month as an
adverse event. Certainly the patient is entitled to expect to
be free of the need for additional revascularization for at
least a month.
METHODS
The study was approved by the Institutional Review Board
of the Medlantic Research Institute. Each patient provided
verbal permission before a telephone questionnaire was
undertaken.
Patients. One thousand twenty-nine consecutive patients
underwent PTCI during the four-month period from Sep-
tember 1 to December 31, 1996 in the catheterization
laboratory of this institution. The 967 (94.0%) in whom
one-month follow-up information could be obtained form
the basis of this report. If a patient underwent more than
one PTCI during this time frame, the initial one was taken
as the index procedure.
Operators. The procedures were carried out by 37 different
operators. Each had been credentialled to perform PTCI
after review by the Peer Review Committee of the labora-
tory. Each met the criteria for training and experience
established by that committee. They were grouped with
regard to the number of PTCI procedures personally per-
formed during the 12-month period from July 1, 1996–June
30, 1997. Operator groups were selected prior to the
analysis with reference to the American College of Cardi-
ology threshold of 75 cases annually and with the intention
of having (with the exception of the very high volume
operators) a relatively equal distribution of patients (Table
1). The rate of follow-up was slightly lower (87%) in the
patients of operators performing 75–199 cases annually. It
was 93% in patients of those performing ,50 and 95% in
those of operators in the other two groups. Thus, the
conclusions of the analysis are not likely to be affected.
Data collection. As is routine in this laboratory, the
operating cardiologist or an assistant completed a report
form describing the baseline clinical characteristics of each
patient and the location and complexity of each target
lesion. Target lesions were assigned a complexity score
[AHA/ACC classification (14)] by the operating cardiolo-
gist based on visual inspection. To facilitate the analysis of
patient-based outcomes, in any instance of multilesion
treatment each patient was assigned complexity category
based on the most complex lesion targeted. Moreover,
patients were assigned to the saphenous vein graft group if
a stenosis in such a conduit was treated.
To collect information regarding the subsequent hospital
course, independent chart review was conducted by specially
trained quality assurance nurses to identify the following
hospital complications: death from any cause, same admis-
sion coronary artery bypass surgery (CABG), myocardial
infarction or an additional PTCI for recurrent symptoms.
Telephone follow-up was initiated in March 1997 and
completed in December 1997. Information regarding the
patient’s course subsequent to hospital discharge was ob-
tained from contact with the patient or with his or her
physician. Contact was attempted no sooner than six
months following the index PTCI. The occurrence of death
or heart attack and the need for CABG or repeat PTCI was
recorded. All additional PTCI’s were performed at this
institution and records were, therefore, available for review.
Only those performed for recurrent unstable symptoms were
tallied.
Definition of terms. Baseline variables were identified by
the operator or his assistant. Diabetes was noted when a
Abbreviations and Acronyms
CABG 5 coronary artery bypass surgery
MACE 5 major adverse cardiac event (death,
myocardial infarction, symptom-driven
revascularization)
PTCI 5 percutaneous transluminal coronary
intervention
Table 1. Annual and Four-Month Operator Volume
Annual
Volume No.
4-Month
Volume
1-Month
Follow-up
,50 18 149 139 (93.3%)
50–74 9 154 147 (95.5%)
75–200 4 106 92 (86.8%)
.200 6 620 589 (95.0%)
Total 37 1,029 967 (94.0%)
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patient provided that history. Renal failure was entered
when the admission serum creatinine $2 mg/dl.
Outcome variables were identified by quality assurance
nurses or by telephone contact. Any death, whether
procedure-related or not, was tallied. Myocardial infarction
was noted when a clinical diagnosis was made in-hospital of
Q-wave or non-Q-wave infarction or when, on telephone
contact, the patient reported a hospital admission for “heart
attack” subsequent to discharge.
Two combined outcome variables were created to provide
a sufficient number of events for multivariate analysis. First,
a major adverse cardiac event (MACE) was tallied when
death from any cause, myocardial infarction, CABG or
additional PTCI was recorded. Second, after univariate
analysis suggested that the observed differences between
operator groups was accounted for by the frequency of
additional revascularization, the outcome variable, addi-
tional revascularization, was created to include any patient
having CABG or an additional symptom-driven PTCI
during follow-up.
Statistical analysis. All data were entered into a comput-
erized database. Demographic, baseline clinical, procedural
and outcome variables were analyzed using standard statis-
tical methods. Continuous variables are presented as the
mean 6 standard deviation and comparisons were made by
means of analysis of variance. Discrete variables are pre-
sented as percentages and were compared by means of
contingency tables and chi-square analysis with Yates cor-
rection. Fisher’s exact test was employed when appropriate.
A p , 0.05 was considered significant.
Stepwise multivariate logistic regression (15) was used to
identify baseline characteristics associated with each of the
two combined outcome variables. Those univariately asso-
ciated at a p , 0.2 level were tested in the multivariate
models. From the independent risk factors determined by
multivariate analysis, the expected risk of an event was
calculated for each patient from the formula:
E 5
exp~b1X1 1 b1X2 . . . 1 bnXn 1 C!
1 1 @exp ~b1X1 1 b2X2 . . . 1 bnXn 1 C!#
where: E 5 expected probability of an event in an individual
patient, beta 5 coefficient describing the relationship of the
independent to the dependent variable (outcome), X 5
presence of an independent variable in the patient, and C 5
constant.
The expected event rate for patients treated by each
operator group was compared with the observed event rate.
RESULTS
Baseline characteristics. The baseline clinical and angio-
graphic characteristics of the patients are listed in Table 2.
Differences in those treated by different operator groups
reflect the varying practice patterns of the physicians within
the group. A distinct trend across volume groups was
apparent only for the performance of multilesion PTCI.
Patients treated by operators who performed .200 cases
annually differed in several respects from those of the other
three groups reflecting the referral nature of the practice of
the highest volume operators. Operators in that group
treated a greater percentage of patients with prior CABG
and prior PTCI, more patients with Type-C lesions, tar-
geted more saphenous vein graft stenoses and performed
more multilesion procedures. On the other hand, the
patients of these highest volume operators less frequently
had unstable angina at presentation.
Table 2. Baseline Clinical and Angiographic Characteristics
<50 50–74 75–200 >200
p
Value
Number 139 147 92 589
Age (yrs) 65.9 6 11.4 63.2 6 12.0 63.5 6 11.6 65.0 6 11.0 0.133
Female 53 (38.1%) 34 (23.1%) 36 (39.1%) 157 (26.7%) 0.003
Diabetes 36 (25.9%) 38 (25.9%) 31 (33.7%) 165 (28.0%) 0.547
Renal failure 13 (9.4%) 11 (7.5%) 4 (4.4%) 28 (4.8%) 0.138
Prior CABG* 30 (21.7%) 29 (19.97%) 17 (18.5%) 203 (35.8%) ,0.001
Prior PTCI* 53 (38.4%) 54 (37.0%) 25 (27.2%) 275 (48.6%) ,0.001
Indication† 0.004
Stable angina 14 (10.1%) 23 (15.9%) 10 (11.0%) 126 (23.3%)
Unstable angina 113 (81.9%) 114 (78.6%) 73 (80.2%) 385 (71.2%)
AMI #48 hr 11 (8.0%) 8 (5.5%) 8 (8.8%) 30 (5.6%)
Cardiogenic shock 3 (2.2%) 0 3 (3.3%) 7 (1.2%) 0.146
$2 lesions 46 (33.1%) 57 (38.8%) 43 (46.7%) 332 (56.4%) ,0.001
Type C lesion‡ 45 (34.5%) 58 (40.6%) 33 (35.9%) 305 (54.3%) ,0.001
Total occlusion 19 (14.1%) 12 (8.2%) 17 (18.5%) 75 (12.8%) 0.128
Saphenous vein 11 (8.0%) 12 (8.2%) 4 (4.4%) 93 (15.8%) ,0.001
*Data available in 941 (97.4%) of patients; †Data available in 914 (94.6%) of patients; ‡Data available in 926 (95.9%) of patients.
AMI 5 acute myocardial infarction; CABG 5 coronary artery bypass surgery; PTCI 5 percutaneous transluminal coronary
intervention.
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Unadjusted outcomes. As expected, the overall MACE
rate at one month was nearly double that encountered
in-hospital (9.9% vs. 5.1%, Table 3). Interesting differences
may be seen in the nature of the adverse events during the
two time frames. Death or myocardial infarction not asso-
ciated with any additional revascularization accounted for
20 (40.8%) of the 49 in-hospital complications but only 5
(10.6%) of the 47 MACE incidents between hospital
discharge and one month. Indeed, symptom-driven repeat
PTCI was involved in 42 (89.4%) of the 47 MACE
incidents occurring after hospital discharge.
Table 4 lists the frequency of MACE at one month
sorted by operator volume group. The rate for operators
with an annual volume ,50 was 15.1%, higher than that
(9.1%) of the other three groups (p 5 0.040). This differ-
ence was determined by the greater frequency with which
additional revascularization procedures were required in the
lowest volume group (13.7% vs. 6.3%, p 5 0.004). There
was no difference among the groups for the frequency of
death or myocardial infarction.
Risk-adjusted outcomes at one month. Table 5 lists the
baseline variables independently associated with each of the
two selected combined outcome events after adjustment by
means of stepwise logistic regression. Any prior revascular-
ization procedure and myocardial infarction within 48 hours
of the index PTCI were independent predictors of both
MACE and need for additional revascularization. The
presence of cardiogenic shock at the index procedure was an
independent predictor only of MACE. The c-statistic for
accuracy of the model was 0.65 for one-month MACE and
0.64 for need for additional revascularization by one month.
Table 6 and Figure 1 depict the expected and observed
event rates for the operator groups. Only operators in the
lowest volume group had outcomes significantly different
from those expected. The frequencies of both MACE and
repeat revascularization in that group were greater in pa-
tients treated by that group of operators. Indeed, the
observed frequency of repeat revascularization was nearly
twice the expected rate.
Intergroup variation in treatment strategy. We sought to
identify differences in procedural strategies that might
account for the differences in the observed outcomes.
Distinct differences were apparent (Table 7). Operators
performing .200 cases annually employed stents (70.5% vs.
47.6%, p , 0.001) and debulking devices (atherectomy or
laser angiography) (28.2% vs. 11.4%, p , 0.001) more
frequently than operators in the other three groups. The
frequency of MACE was similar for patients receiving
stents as compared with those who did not (p 5 0.407).
Those in whom stents were deployed had fewer repeat
revascularizations, but the difference did not reach statistical
significance (7.2% vs. 10.5%, p 5 0.099). When stent use
and operator volume were added to the multivariate model,
Table 3. In-Hospital and One-Month MACE
In-Hospital
Discharge
to
1-Month 1-Month
*Death 15 (1.6%) 2 (0.2%) 17 (1.8%)
*Myocardial infarct 16 (1.7%) 9 (0.9%) 25 (2.6%)
*CABG 20 (2.1%) 14 (1.4%) 34 (3.5%)
*Additional PTCI 9 (0.9%) 32 (3.3%) 41 (4.2%)
Any MACE 49 (5.1%) 47 (4.9%) 96 (9.9%)
Additional revascularization 29 (3.0%) 42 (4.3%) 71 (7.3%)
*A patient may have had more than one of these events.
CABG 5 coronary artery bypass surgery; MACE 5 major adverse cardiac event;
PTCI 5 percutaneous transluminal coronary intervention.
Table 4. Major Cardiac Events at One Month
<50 50–74 75–200 >200
p
Value
Number 139 147 92 589
Death 3 (2.2%) 1 (0.7%) 1 (1.1%) 12 (2.0%) 0.654
Myocardial infarction 4 (2.9%) 3 (2.0%) 1 (1.1%) 17 (2.9%) 0.741
CABG 9 (6.5%) 5 (3.4%) 3 (3.3%) 17 (2.9%) 0.231
PTCI 10 (7.2%) 2 (1.4%) 3 (3.3%) 26 (4.4%) 0.098
Any revascularization 19 (13.7%) 7 (4.8%) 5 (5.4%) 40 (6.8%) 0.016
Any MACE 21 (15.1%) 9 (6.1%) 6 (6.5%) 60 (10.2%) 0.051
CABG 5 coronary artery bypass surgery; MACE 5 major adverse cardiac event; PTCI 5 percutaneous transluminal coronary
intervention.
Table 5. Independent Predictors at One Month
Beta-
coefficient OR 95% CI
p
Value
Prior CABG 0.5966 1.82 1.14, 2.89 0.012
Prior PTCI 0.5084 1.66 1.05, 2.63 0.030
Myocardial infarction
,48 hrs
1.0977 3.00 1.40, 6.43 0.005
Cardiogenic shock 1.7894 5.99 1.74, 20.6 0.005
Repeat Revascularization
Prior CABG 0.6048 1.83 1.09, 3.07 0.022
Prior PTCI 0.6922 2.00 1.19, 3.36 0.009
Myocardial infarction
,48 hrs
1.2139 3.37 1.53, 7.39 0.003
CABG 5 coronary artery bypass surgery; CI 5 confidence interval; OR 5 odds ratio;
PTCI 5 percutaneous transluminal coronary intervention.
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the latter continued to be an independent predictor of both
outcome variables while stenting was not. The frequency of
neither MACE (11.5% vs. 12.4%, p 5 0.780) nor need for
repeat revascularization (7.2% vs. 8.8%, p 5 0.533) was
different with regard to use of a debulking device.
Abciximab was employed in 84 (8.7%) of patients. The
group of operators performing between 50 to 74 cases
annually used the agent more often than the other three
groups (15.7% vs. 8.2%, p 5 0.018). Abciximab use was
associated with more frequent MACE (20.2% vs. 11.5%,
p 5 0.030) but not repeat revascularization by one month
(p 5 0.573). The increased frequency of MACE in patients
treated with abciximab undoubtedly relates to the tendency
of operators in this laboratory to limit the use of this agent
to “high-risk” patients or as a “bail out” strategy. Thus, no
systematic variation in the use of these treatment strategies
accounts for the difference in outcome between operator
groups.
DISCUSSION
These data indicate that the use of one-month MACE rates
following PTCI provides a valid basis for analysis of
operator outcomes. The fact that our findings are consistent
with those reported from the analysis of very large, multi-
center data sets (2–5) supports this conclusion. We used
data from 967 patients to demonstrate that, as a group,
physicians performing $50 cases annually had better out-
comes than the group performing ,50. The difference was
determined by the greater frequency with which additional
revascularization was carried out. In fact, the observed rate
of an additional PTCI or CABG within a month of the
index procedure was nearly double that predicted by the
multivariate model in patients treated by physicians per-
forming ,50 cases annually (Table 6).
Unlike the large multicenter analyses (2–5), we tallied the
need for an additional PTCI during the first month after the
index procedure as an adverse event. Counting such events
substantially enhanced the statistical power of the analysis.
Indeed, almost 90% of events between hospital discharge
and one-month involved repeat PTCI. Thus, the greater
frequency of PTCI between hospital discharge and one
month in patients treated by the operator group with the
lowest annual volume in large measure accounts for the
differences observed. We believe the inclusion of such end
points to be justified since we tallied only those undertaken
because of renewed or continued symptoms.
Table 6. Observed and Expected Event Rates
Number
<50 50–74 75–200 >200
139 147 92 529
MACE rate
Expected (95% CI) 9.7% (4.7%, 14.6%) 8.5% (4.0%, 13.0%) 9.7% (3.6%, 15.7%) 10.1% (7.7%, 12.6%)
Observed 15.1% 6.1% 6.5% 10.2%
Observed/expected ratio 1.58 0.72 0.67 1.01
Revascularization rate
Expected (95% CI) 7.1% (2.8%, 11.4%) 6.6% (2.6%, 10.7%) 6.6% (1.5%, 11.7%) 7.9% (5.7%, 10.1%)
Observed 13.8% 4.8% 5.4% 6.8%
Observed/expected ratio 1.94 0.72 0.82 0.86
CI 5 confidence interval; MACE 5 major adverse cardiac event; OR 5 odds ratio.
Figure 1. The observed one-month event rate for each operator
group is indicated by a star and is displayed against the expected
rate with its 95% confidence intervals for both MACE (A) and
additional revascularization (B). Notice that only the outcomes of
the group of operators performing ,50 cases annually fall outside
the 95% confidence limits of the expected rate for their patient
population. MACE 5 major adverse cardiac event.
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We are aware of only one other instance in which
one-month outcomes were used to assess operator perfor-
mance. That study also found a better performance by
“high-volume operators.” Kastrati et al. (16) used a 30-day
combined variable of death, myocardial infarction and
CABG to analyze operator performance with stent implan-
tation. In their study, higher volume operators had better
outcomes.
Potential advantages of the use of one-month MACE.
Importantly, the greater statistical power provided by one-
month outcomes allows analysis of the variation between
operator groups in a single institution. Utilization of results
from a single laboratory overcomes many of the criticisms of
the use of large, multicenter databases. Many of the poten-
tial reasons for variability in operator performance are
eliminated since all procedures are performed in uniform
environment. Moreover, risk adjustment will almost cer-
tainly be more consistent.
Shook et al. (17) in a previous study of the relationship
between operator volume and outcome from a single insti-
tution reviewed 2,350 PTCI procedures performed over a
three-year period. They found that more emergency
CABGs were required and more in-hospital morbidity was
encounted in patients treated by the “low-volume operator”
group.
It does not necessarily follow that all operators perform-
ing ,50 cases annually have less than optimal results. In our
analysis we found many physicians in the lowest volume
group with quite good outcomes (Fig. 2). There was a wide
scatter reflecting the small sample size for these operators.
What is needed, therefore, is a way to evaluate the perfor-
mance of individual operators. Such a means of evaluation is
particularly important to directors of cardiac catheterization
laboratories and divisions of cardiology since it is on their
shoulders that the expert panel of the American College of
Cardiology placed the responsibility for operator evaluation
(1).
The greater statistical power provided by one-month
MACE rates may offer a partial solution to this problem. A
sample-size calculation indicates that, given an event rate of
9.9%, a 2.5-fold increase over the laboratory standard can be
detected with a sample size of about 40 patients (alpha 5
0.05, power 5 0.80). Using in-hospital complications (typ-
ically about 5%), a sample size of 90 is needed. Thus, while
not ideal, one-month MACE is potentially useful to eval-
uate even lower volume operators.
Appropriateness of the use of one-month outcome. Our
assumption that the frequency of one-month MACE
largely reflects procedure-related factors is supported not
only by the previously cited reports of angiographic and
intracoronary ultrasound observations (11–13) but also by
our own data set. All of the difference in performance
between operator groups is determined during the first
month. The frequency of MACE was similar in all groups
between one and six months (Fig. 3). It is in the latter time
frame that restenosis rather than procedural factors will
account for the vast majority of events.
Laboratory environment. The cardiac catheterization lab-
oratory at this institution provides an advantageous envi-
ronment in which to address operator volume and out-
comes. In many respects it is a microcosm of the practice of
Table 7. Procedural Differences Between Volume Groups
<50 50–74 75–200 >200 p Value
Number 139 147 92 589
Stent use 63 (45.3%) 78 (53.1%) 39 (42.4%) 415 (70.5%) ,0.001
Debulking device* 6 (4.3%) 24 (16.3%) 13 (14.1%) 166 (28.2%) ,0.001
Abciximab use 9 (6.5%) 21 (14.3%) 9 (9.8%) 45 (7.6%) 0.055
*Atherectomy or laser angioplasty.
Figure 2. Scatter plots are shown demonstrating individual oper-
ator frequency of MACE (A) and of additional revascularization
(B) at one month. Note the wide scatter in event rates for the
operators performing ,50 cases annually. MACE 5 major adverse
cardiac event.
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interventional cardiology in the U.S. The laboratory is open
to all qualified cardiologists, and operators are, therefore,
heterogeneous with regard to experience and annual vol-
ume. Twenty-three of the 37 operators reviewed for this
analysis had been active in interventional cardiology for
more than 8 years and in one instance for more than 20
years. Thirteen of the remaining 14 were graduates of
interventional fellowship programs. Nearly three-quarters of
the physicians perform fewer than the $75 cases annually
proposed by the expert panel, but the majority of patients
are treated by individuals who do .200. Moreover, the
laboratory is unquestionably high-volume. Nearly 4,000
PTCI procedures are performed annually. Philosophically
and operationally, the more experienced operators and
support staff are committed to assisting all physicians in the
safe and effective care of their patients. Thus, the perfor-
mance of low-volume operators is likely to be enhanced by
participation in this high-volume laboratory.
Study limitations. This cohort study was conducted as part
of an ongoing quality assurance program in this laboratory.
It was intended to investigate the practicality of using
one-month outcomes on a routine basis. Our resources were
not adequate to allow either collection of all of the 29
baseline variables identified by Block et al. (18) as having an
association with adverse outcomes after PTCI or for inde-
pendent review of all angiograms. We used twelve baseline
variables that are relatively free of potential for operator bias
(Table 2). Importantly, only a few angiographic character-
istics of target lesions were included since independent
review was not available. None proved to be an independent
predictor of one-month events.
All outcome variables are “hard” end points with the
exception of the occurrence of myocardial infarction. For
that variable, problems in definition exist. The frequency of
in-hospital non-Q-wave infarction may have been influ-
enced by the frequency with which the operating cardiolo-
gist obtained serum indexes of myocardial injury. Moreover,
the identification of myocardial infarction after hospital
discharge depended on patient recall and may have included
omissions or misidentification of infarction. Fortunately,
the occurrence of myocardial infarction did not contribute
to the observed differences in outcome between operator
groups.
While the risk-adjustment analysis yielded results that are
intuitively reasonable, some of its aspects could be im-
proved. Certain of the baseline variables discarded as not
independently related were either not precisely defined prior
to data collection (i.e., unstable angina) or were subject to
observer bias (i.e., lesion complexity). Moreover, other
potentially important outcome predictors were not analyzed
(i.e., ejection fraction) because of incomplete data. Thus,
the multivariate model needs validation and potentially,
modification.
We cannot exclude the possibility that one or more
operators performed PTCI in other laboratories and were,
as a consequence, misclassified as “low-volume.” Such a
misclassification could, theoretically, either enhance or de-
tract from the observed performance of the ,50 case group.
Unfortunately, reliable data on operator performance at
competing institutions were not available. Based on our
knowledge of community practice, however, we do not
believe that any possible misclassification adversely affected
the observed performance of the “low-volume group.”
Conclusion. Risk-adjusted one-month MACE rates pro-
vide data relating operator volume and outcome of PTCI
that is consistent with the results of the analyses of large
multicenter databases. Moreover, the greater statistical
power provided by the overall rate of MACE and, particu-
larly, of the need for performance of additional revascular-
ization by one month appear to offer an option for analyzing
individual physicians with interventional practices of 40 to
50 procedures annually.
Figure 3. Bar graphs depict the frequency of MACE (A) and
additional revascularization (B) for the operator groups at one
month and between one and six months. The difference between
groups is apparent at one month. Event rates between one and six
months are similar for all groups. MACE 5 major adverse cardiac
event.
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